Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases
Deobrat Dixit(Columbia University Irving Medical Center), Jeremy N. Rich(University of North Carolina at Chapel Hill), Qiulian Wu(University of California San Diego), Shideng Bao(Cleveland Clinic Lerner College of Medicine), Derrick Lee(Twitter (United States)), Briana C. Prager(University of California San Diego), Linjie Zhao(UPMC Hillman Cancer Center), Robert J. Wechsler‐Reya(Columbia University Irving Medical Center), Ryan C. Gimple(Washington University in St. Louis), Deguan Lv(University of Pittsburgh), Donglim Esther Park(University of California San Diego), Shira Yomtoubian(University of California San Diego), Zhixin Qiu(University of California San Diego), Reilly L. Kidwell(University of California, San Francisco), Guoxin Zhang(University of California San Diego), Tyler E. Miller(Case Comprehensive Cancer Center)
Cited by 37
Related Papers
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|607
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
|Genes & Development|2019|556
c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells
|PLoS ONE|2008|422
Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth
|Stem Cells|2009|336
Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities
|Nature Genetics|2022|296